Cost-effective treatment of low-risk carcinoma not invading bladder muscle

BJU International

Volumn 111, Issue 3 B, 2013, Pages E78-E84

  Green, David A ^a   Rink, Michael ^a,b   Cha, Eugene K ^a   Xylinas, Evanguelos ^c   Chughtai, Bilal ^a   Scherr, Douglas S ^a   Shariat, Shahrokh F ^a   Lee, Richard K ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Paris 5 University ^*  (France)

Author keywords

bladder cancer; chemotherapy; cystoscopy; efficiency; intravesical instillation

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BLADDER CARCINOMA; CANCER RECURRENCE; CAUTERIZATION; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MEDICARE; NON MUSCLE INVASIVE BLADDER CARCINOMA; PEER REVIEW; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RECURRENCE RISK; SENSITIVITY ANALYSIS; TRANSURETHRAL RESECTION; TREATMENT OUTCOME;

EID: 84874670940     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11454.x     Document Type: Article

References (16)

1. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R,. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003; 21: 1315-30
2. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al,. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 466-5
3. Hall MC, Chang SS, Dalbagni G, et al,. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007; 178: 2314-30
4. Sylvester RJ, Oosterlinck W, van der Meijden AP,. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004; 171: 2186-90
5. Gudjõnsson S, Adell L, Merdasa F, et al,. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol 2009; 55: 773-80
6. Herr HW, Donat SM, Reuter VE,. Management of low grade papillary bladder tumors. J Urol 2007; 178: 1201-5
7. Donat SM, North A, Dalbagni G, Herr HW,. Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm. J Urol 2004; 171: 636-9
8. Babjuk M, Oosterlinck W, Sylvester R, et al,. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011; 59: 997-1008
9. Kulkarni GS, Finelli A, Fleshner NE, Jewett MA, Lopushinsky SR, Alibhai SM,. Optimal management of high-risk T1G3 bladder cancer: a decision analysis. PLoS Med 2007; 4: e284
10. Kulkarni GS, Alibhai SM, Finelli A, et al,. Cost-effectiveness analysis of immediate radical cystectomy versus intravesical bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer. Cancer 2009; 115: 5450-9
11. Gofrit ON, Pode D, Lazar A, Katz R, Shapiro A,. Watchful waiting policy in recurrent Ta G1 bladder tumors. Eur Urol 2006; 49: 303-6
12. Berrum-Svennung I, Granfors T, Jahnson S, Boman H, Holmäng S,. A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J Urol 2008; 179: 101-5
13. Feifer A, Xie X, Brophy JM, Segal R, Kassouf W,. Contemporary cost analysis of single instillation of mitomycin after transurethral resection of bladder tumor in a universal health care system. Urology 2010; 76: 652-6
14. Rao PK, Stephen Jones J,. Routine perioperative chemotherapy instillation with initial bladder tumor resection: a reconsideration of economic benefits. Cancer 2009; 115: 997-1004
15. Herr HW, Donat SM, Dalbagni G,. Correlation of cystoscopy with histology of recurrent papillary tumors of the bladder. J Urol 2002; 168: 978-80
16. Rink M, Cha EK, Green D, et al,. Biomolecular predictors of urothelial cancer behavior and treatment outcomes. Curr Urol Rep 2012; 13: 122-35